Physician profile
Michael Given
NPI 1104898980
$8,902.80
in general payments reported to CMS, 2019-2025
36 companies · $2,381 in 2025
The $2,381 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $714 · 2021: $990 · 2022: $1,394 · 2023: $1,333 · 2024: $1,512 · 2025: $2,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,166 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,165.94 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,426.13 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,980.86 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Grifols USA, LLC | $875.44 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $495.49 | 2020-2025 | Ofev, Jascayd |
| Insmed, INC. | $457.40 | 2022-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $425.42 | 2020-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $303.98 | 2024-2025 | Glassia |
| Amgen INC. | $265.78 | 2020-2025 | Tezspire |
| Genzyme Corporation | $218.39 | 2021-2025 | |
| Verona Pharma, INC. | $176.96 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $156.20 | 2023-2025 | Inspire |
| Axsome Therapeutics, INC. | $125.00 | 2023 | Auvelity |
| Paratek Pharmaceuticals, INC. | $115.17 | 2023-2025 | Nuzyra |
| United Therapeutics Corporation | $107.69 | 2023 | |
| Vifor Pharma, INC. | $90.75 | 2024-2025 | Zemaira, Veltassa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $79.78 | 2019-2023 | Yupelri |
| Baxter Healthcare | $72.25 | 2022-2024 | Hillrom - Life 2000 Ventilation System |
| Sanofi-Aventis U.S. LLC | $59.99 | 2023 | |
| Philips North America LLC | $50.82 | 2023-2024 | (Ak6) Vest Therapy |
| Ani Pharmaceuticals, INC. | $42.24 | 2023-2024 | Purified Cortrophin Gel |
| Pulmonx Corporation | $37.96 | 2024-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Merck Sharp & Dohme LLC | $33.39 | 2023-2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $33.25 | 2024 | |
| Shire North American Group INC | $31.54 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $28.38 | 2024 | Arcalyst |
| Viatris Specialty LLC | $26.96 | 2025 | Yupelri |
| Abbott Laboratories | $25.33 | 2024 | Jot Dx |
| Lexicon Pharmaceuticals, INC. | $24.62 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $24.41 | 2024 | Uptravi |
| Novo Nordisk INC | $17.96 | 2019 | |
| Genentech USA, INC. | $17.22 | 2020 | |
| Nobel Biocare USA | $16.66 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.76 | 2024 | Xarelto |
| Electromed, INC. | $15.22 | 2024 | Smartvest |
| Harmony Biosciences LLC | $14.67 | 2024 | |
| Fisher & Paykel Healthcare INC | $13.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Given listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.